[{"orgOrder":0,"company":"BioArctic AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWEDEN","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Ban2401","moa":"Amyloid beta plaque","graph1":"Neurology","graph2":"Phase III","graph3":"BioArctic AB","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BioArctic AB \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"BioArctic AB \/ Not Applicable"},{"orgOrder":0,"company":"BioArctic AB","sponsor":"BioArctic AB","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"NORWAY","productType":"Undisclosed","year":"2020","type":"Agreement","leadProduct":"Undisclosed","moa":"Apolipoprotein E","graph1":"Neurology","graph2":"Discovery","graph3":"BioArctic AB","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"BioArctic AB \/ BioArctic","highestDevelopmentStatusID":"2","companyTruncated":"BioArctic AB \/ BioArctic"},{"orgOrder":0,"company":"BioArctic AB","sponsor":"Eisai","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Lecanemab","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"BioArctic AB","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BioArctic AB \/ BioArctic","highestDevelopmentStatusID":"12","companyTruncated":"BioArctic AB \/ BioArctic"},{"orgOrder":0,"company":"BioArctic AB","sponsor":"Eisai","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Lecanemab","moa":"Amyloid beta plaque","graph1":"Neurology","graph2":"Approved","graph3":"BioArctic AB","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous infusion","sponsorNew":"BioArctic AB \/ BioArctic AB","highestDevelopmentStatusID":"12","companyTruncated":"BioArctic AB \/ BioArctic AB"},{"orgOrder":0,"company":"BioArctic AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Undisclosed","year":"2021","type":"Not Applicable","leadProduct":"AD1503","moa":"","graph1":"Neurology","graph2":"Discovery","graph3":"BioArctic AB","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"BioArctic AB \/ Not Applicable","highestDevelopmentStatusID":"2","companyTruncated":"BioArctic AB \/ Not Applicable"},{"orgOrder":0,"company":"BioArctic AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Lecanemab","moa":"Amyloid beta protein A4","graph1":"Neurology","graph2":"Phase III","graph3":"BioArctic AB","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous infusion","sponsorNew":"BioArctic AB \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"BioArctic AB \/ Not Applicable"},{"orgOrder":0,"company":"BioArctic AB","sponsor":"Eisai","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Lecanemab","moa":"Amyloid beta plaque","graph1":"Neurology","graph2":"Phase III","graph3":"BioArctic AB","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous infusion","sponsorNew":"BioArctic AB \/ Eisai","highestDevelopmentStatusID":"10","companyTruncated":"BioArctic AB \/ Eisai"},{"orgOrder":0,"company":"BioArctic AB","sponsor":"Eisai","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Lecanemab","moa":"Amyloid beta plaque","graph1":"Neurology","graph2":"Phase III","graph3":"BioArctic AB","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BioArctic AB \/ Eisai","highestDevelopmentStatusID":"10","companyTruncated":"BioArctic AB \/ Eisai"},{"orgOrder":0,"company":"BioArctic AB","sponsor":"Eisai","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Lecanemab","moa":"Amyloid beta plaque","graph1":"Neurology","graph2":"Approved","graph3":"BioArctic AB","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BioArctic AB \/ BioArctic","highestDevelopmentStatusID":"12","companyTruncated":"BioArctic AB \/ BioArctic"},{"orgOrder":0,"company":"BioArctic AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"ABBV-0805","moa":"Alpha synuclein","graph1":"Neurology","graph2":"Phase I","graph3":"BioArctic AB","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BioArctic AB \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"BioArctic AB \/ Not Applicable"},{"orgOrder":0,"company":"BioArctic AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Lecanemab","moa":"Amyloid beta plaque","graph1":"Neurology","graph2":"Phase III","graph3":"BioArctic AB","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BioArctic AB \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"BioArctic AB \/ Not Applicable"},{"orgOrder":0,"company":"BioArctic AB","sponsor":"Eisai","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Lecanemab","moa":"Amyloid beta protein A4","graph1":"Neurology","graph2":"Phase III","graph3":"BioArctic AB","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BioArctic AB \/ Eisai","highestDevelopmentStatusID":"10","companyTruncated":"BioArctic AB \/ Eisai"},{"orgOrder":0,"company":"BioArctic AB","sponsor":"Eisai","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Lecanemab","moa":"Amyloid beta","graph1":"Neurology","graph2":"Approved","graph3":"BioArctic AB","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BioArctic AB \/ Bioarctic","highestDevelopmentStatusID":"12","companyTruncated":"BioArctic AB \/ Bioarctic"},{"orgOrder":0,"company":"BioArctic AB","sponsor":"AbbVie Inc","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Large molecule","year":"2022","type":"Termination","leadProduct":"ABBV-0805","moa":"Alpha synuclein","graph1":"Neurology","graph2":"Phase I","graph3":"BioArctic AB","amount2":0.76000000000000001,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0.76000000000000001,"dosageForm":"Intravenous Infusion","sponsorNew":"BioArctic AB \/ AbbVie","highestDevelopmentStatusID":"6","companyTruncated":"BioArctic AB \/ AbbVie"},{"orgOrder":0,"company":"BioArctic AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"ABBV-0805","moa":"Alpha synuclein","graph1":"Neurology","graph2":"Phase I","graph3":"BioArctic AB","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BioArctic AB \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"BioArctic AB \/ Not Applicable"},{"orgOrder":0,"company":"BioArctic AB","sponsor":"Eisai","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Lecanemab","moa":"Amyloid beta plaque","graph1":"Neurology","graph2":"Approved","graph3":"BioArctic AB","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous injection","sponsorNew":"BioArctic AB \/ BioArctic","highestDevelopmentStatusID":"12","companyTruncated":"BioArctic AB \/ BioArctic"},{"orgOrder":0,"company":"BioArctic AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Undisclosed","year":"2022","type":"Not Applicable","leadProduct":"Undisclosed","moa":"","graph1":"Neurology","graph2":"Preclinical","graph3":"BioArctic AB","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"BioArctic AB \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"BioArctic AB \/ Not Applicable"},{"orgOrder":0,"company":"BioArctic AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"PD-BT2238","moa":"","graph1":"Neurology","graph2":"Preclinical","graph3":"BioArctic AB","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"BioArctic AB \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"BioArctic AB \/ Not Applicable"},{"orgOrder":0,"company":"BioArctic AB","sponsor":"Eisai","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Lecanemab","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"BioArctic AB","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"BioArctic AB \/ BioArctic AB","highestDevelopmentStatusID":"12","companyTruncated":"BioArctic AB \/ BioArctic AB"},{"orgOrder":0,"company":"BioArctic AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Lecanemab-irmb","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"BioArctic AB","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"BioArctic AB \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"BioArctic AB \/ Not Applicable"},{"orgOrder":0,"company":"BioArctic AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"Lecanemab-irmb","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"BioArctic AB","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"BioArctic AB \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"BioArctic AB \/ Not Applicable"},{"orgOrder":0,"company":"BioArctic AB","sponsor":"Eisai","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"Lecanemab","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"BioArctic AB","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"BioArctic AB \/ BioArctic AB","highestDevelopmentStatusID":"12","companyTruncated":"BioArctic AB \/ BioArctic AB"},{"orgOrder":0,"company":"BioArctic AB","sponsor":"Eisai Inc","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Large molecule","year":"2024","type":"Agreement","leadProduct":"BAN2802","moa":"","graph1":"Neurology","graph2":"Preclinical","graph3":"BioArctic AB","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"BioArctic AB \/ Eisai Inc","highestDevelopmentStatusID":"4","companyTruncated":"BioArctic AB \/ Eisai Inc"},{"orgOrder":0,"company":"BioArctic AB","sponsor":"Eisai","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"Lecanemab","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"BioArctic AB","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"BioArctic AB \/ Eisai","highestDevelopmentStatusID":"14","companyTruncated":"BioArctic AB \/ Eisai"},{"orgOrder":0,"company":"BioArctic AB","sponsor":"Eisai","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"Lecanemab","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"BioArctic AB","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"BioArctic AB \/ Eisai","highestDevelopmentStatusID":"14","companyTruncated":"BioArctic AB \/ Eisai"},{"orgOrder":0,"company":"BioArctic AB","sponsor":"Eisai","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"Lecanemab","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"BioArctic AB","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"BioArctic AB \/ BioArctic AB","highestDevelopmentStatusID":"14","companyTruncated":"BioArctic AB \/ BioArctic AB"}]
Find Clinical Drug Pipeline Developments & Deals by BioArctic AB
Details :
Leqembi (lecanemab) is an IgG1 monoclonal antibody directed against aggregated soluble (protofibril) and insoluble forms of amyloid-beta. It is indicated for the treatment of Alzheimer’s disease.
Details :
Leqembi (lecanemab) is an IgG1 monoclonal antibody directed against aggregated soluble (protofibril) and insoluble forms of amyloid-beta. It is indicated for the treatment of Alzheimer’s disease.
Details :
Leqembi (lecanemab) is an IgG1 monoclonal antibody directed against aggregated soluble (protofibril) and insoluble forms of amyloid-beta. It is indicated for the treatment of Alzheimer’s disease.
Details :
The agreement aims to evaluate BAN2802, a potential new treatment combining BioArctic's proprietary BrainTransporter™ technology with an undisclosed Alzheimer drug candidate.
Details :
Leqembi (lecanemab-irmb) is a humanized IgG1 monoclonal antibody targeting amyloid-beta, being evaluated for IV maintenance dosing in early Alzheimer's disease treatment.
Details :
Leqembi (lecanemab-irmb) is a humanized IgG1 monoclonal antibody directed against aggregated soluble and insoluble amyloid-beta forms. It is indicated for the treatment of Alzheimer’s disease.
Details :
Leqembi (lecanemab-irmb) is a humanized immunoglobulin gamma 1 (IgG1) monoclonal antibody directed against aggregated soluble (protofibril) and insoluble forms of amyloid-beta (Aβ). It is indicated for the treatment of Alzheimer’s disease.
Details :
Lecanemab is an investigational humanized monoclonal antibody for AD. Lecanemab selectively binds and eliminates soluble, toxic amyloid-beta (Aβ) aggregates (protofibrils) that are thought to contribute to the neurotoxicity in AD.
Details :
The PD-BT2238 project is a second-generation alpha-synuclein antibody, combining an oligomer-selective alpha-synuclein antibody with BioArctic's Brain Transporter technology, designed to improve brain exposure.
Details :
Blood-brain barrier protects brain from foreign substances by restricting passage of these substances into brain. The patented technologyhas been developed to facilitate the transport of biopharmaceuticals across this barrier, thereby potentially improvi...
Reset All
